Guangxin Xia

A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles

Guangxin Xia, Wenteng Chen, Jing Zhang et al. · Journal of Medicinal Chemistry · 2014 · 72 citations · Full text

Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization

Lele Zhao, Ying-Qing Wang, Danyan Cao et al. · Journal of Medicinal Chemistry · 2015 · 49 citations · Full text

Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives

Guangxin Xia, Jianfeng Li, Aiming Peng et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 36 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Derivatives +7

Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR

Wenteng Chen, Guangxin Xia, Jing Zhang et al. · ACS Medicinal Chemistry Letters · 2013 · 24 citations · Full text

Drug Target, Quinazoline Analogues, Molecular Biology +23

Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer

Shi Chen, Qian Wang, Xuemei Liao et al. · European Journal of Medicinal Chemistry · 2019 · 24 citations · Full text

Medicinal Chemistry, Health Sciences, Medicine +9